T2 heterogeneity provides a sensitive measure of early tumor response to radiotherapy

Michal R. Tomaszewski, William Dominguez‐Viqueira, Antonio Ortiz, Yu Shi, James Costello, Heiko Enderling, Stephen A. Rosenberg, Robert J. GilliesbioRxiv 2020 · DOI

TL;DR

This paper introduces a novel MRI-based method using T2 relaxation heterogeneity, specifically the Interquartile Range (IQR), to detect early responses to radiotherapy in pancreatic cancer. This approach is more sensitive than traditional metrics and could enable personalized treatment adjustments in real-time.

What Problem Does This Paper Address?

External beam radiotherapy (XRT) is a common cancer treatment, but patient responses vary significantly. Currently, there's a lack of sensitive biomarkers to predict early treatment response, making it difficult to tailor XRT to individual patients. This means many patients receive standardized treatments that may not be optimal, leading to either under- or over-treatment. The authors aim to address this by developing a method to quantify intratumor heterogeneity as an early indicator of response to XRT.

Methods

The core of this research is a novel approach to analyzing Magnetic Resonance Imaging (MRI) data. Specifically, they focus on T2 relaxation measurements, which are already used clinically. Instead of looking at average T2 values, they employ histogram analysis to quantify the heterogeneity of T2 values within a tumor. The key metric they developed is the Interquartile Range (IQR) of T2 values. This metric captures the spread of T2 values, serving as a proxy for structural changes and cellular heterogeneity within the tumor. They applied this method to murine models of pancreatic cancer undergoing XRT, comparing its performance against standard MRI metrics like whole-tumor T2 and Diffusion Weighted Imaging (DWI). Biological validation was performed using quantitative histology.

Datasets

The study utilized two murine models of pancreatic cancer: Panc02 and BXPC3. They also included a small proof-of-concept analysis on T2-weighted MRI scans from two human PDAC patients.

Key Insights and Ideas

  • Heterogeneity as a Biomarker: The central idea is that changes in tumor heterogeneity, as revealed by T2 MRI, are a more sensitive indicator of early radiotherapy response than bulk tumor properties.
  • IQR's Superiority: The Interquartile Range (IQR) of T2 values emerged as a particularly effective metric, outperforming traditional whole-tumor T2 and apparent diffusion coefficient (ADC) metrics in detecting early XRT-induced changes.
  • Biological Underpinnings: The study linked T2 IQR changes to histological findings of increased cellular heterogeneity and necrosis, providing a biological basis for the observed imaging changes.
  • Predictive Power: Early changes in T2 IQR were found to correlate with subsequent tumor volume changes, suggesting its potential for predicting treatment response.
  • Clinical Translatability: The method is designed to work with clinically standard T2-weighted MRI sequences, making it readily applicable in clinical settings.

Key Results

  • Early Detection: T2 IQR showed excellent sensitivity in detecting XRT-induced tumor changes as early as 72 hours after treatment.
  • Performance: T2 IQR outperformed whole-tumor T2 and DWI metrics in detecting these early changes.
  • Correlation with Growth: A stronger early IQR response (increase) was inversely correlated with tumor regrowth, indicating predictive value for treatment response. For example, in Panc02 tumors, a significant negative correlation (r=-0.67, p=0.035) was observed between the 3-day IQR increase and tumor regrowth between days 6 and 9.
  • Histological Validation: T2 IQR changes were consistent with histological findings of increased heterogeneity and necrosis in irradiated tumors.
  • Robustness: The IQR metric demonstrated excellent test-retest robustness, crucial for clinical application.
  • Clinical Relevance: Proof-of-concept analysis on human PDAC scans showed differences in IQR consistent with visual tumor heterogeneity.

Limitations and Future Work

  • T2 Contrast Definition: The authors acknowledge that T2 contrast, while widely used, is less precisely defined biologically than diffusion contrast and can be affected by factors like swelling, blood, and fat. Further measurements may be needed to quantify these influences.
  • Murine Model Limitations: The experiments were performed in subcutaneous models, which may not fully recapitulate the clinical disease. The authors plan validation in more realistic transgenic models and retrospective clinical MR-Linac scans.
  • Immune System Effects: While immunocompetent and deficient models were used, the different patterns of immune infiltration and inflammation in humans compared to mice could alter imaging change dynamics.
  • Future Work: The authors envision applying these findings to clinical data, particularly with the advent of MR-Linac systems that acquire images daily. They suggest that quantitative T2 relaxation measurements, combined with heterogeneity analysis, could be routinely performed in clinics to provide robust and sensitive measures of radiation-induced changes, potentially exceeding the capabilities of ADC for necrosis quantification.

Summary updated

Abstract

Abstract Purpose External beam radiotherapy (XRT) is a widely used cancer treatment, yet responses vary dramatically between patients. These differences are not accounted for in clinical practice, in part due to a lack of sensitive biomarkers of early response. In this work, we test the hypothesis that quantification of intratumor heterogeneity is a sensitive and robust biomarker of early response to XRT. A novel Magnetic Resonance Imaging (MRI) approach is proposed, utilizing histogram analysis of clinically-used T2 relaxation measurements to assess early changes in the tumor heterogeneity following irradiation in murine models of pancreatic cancer, indicative of radiotherapy response. Methods and Materials Dynamic Magnetic Resonance T2 relaxation imaging was performed every 72h following 10 Gy dose XRT in two murine models of pancreatic cancer. Proposed biomarker of radiotherapy response was compared with tumor growth kinetics, and biological validation was performed through quantitative histology analysis. Results Quantification of tumor T2 interquartile range (IQR) as a measure of histogram width showed excellent sensitivity for detection of XRT-induced tumor changes as early as 72h after treatment, outperforming whole tumor T2 and Diffusion weighted MRI metrics. This response was observed both in quantitative T2 maps and in T2-weighted images that are routine in clinical practice. Histological comparison revealed the T2 IQR provides a measure of spatial heterogeneity in tumor cell density, related to radiation-induced necrosis. The early IQR changes were found to presage subsequent tumor volume changes in two distinct pancreatic models, suggesting promise for treatment response prediction. The metric showed excellent test-retest robustness. Conclusions Our preclinical findings indicate that spatial heterogeneity analysis of T2 MRI can provide a sensitive and readily translatable method for early radiotherapy response assessment in pancreatic cancer. We propose that this will be useful in adaptive radiotherapy, specifically in MRI-guided treatment paradigms.
BibTeX
@misc{tomaszewski2020t,
  author = {Michal R. Tomaszewski and William Dominguez‐Viqueira and Antonio Ortiz and Yu Shi and James Costello and Heiko Enderling and Stephen A. Rosenberg and Robert J. Gillies},
  title = {{T2 heterogeneity provides a sensitive measure of early tumor response to radiotherapy}},
  year = {2020},
  doi = {10.1101/2020.04.21.053736},
  howpublished = {bioRxiv},
}
Figure